Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00054691
What this trial is testing

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Who this might be right for
Skin Cancer
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT00124280
What this trial is testing

Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small-cell Lung Carcinoma
Novartis Pharmaceuticals 85
Testing effectiveness (Phase 2)Study completedNCT02025114
What this trial is testing

Selumetinib in Combination With Gefitinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
National Taiwan University Hospital 34
Not applicableStudy completedNCT00091247
What this trial is testing

Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Alliance for Clinical Trials in Oncology 130
Not applicableStudy completedNCT01955681
What this trial is testing

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

Who this might be right for
Locally Advanced or Metastatic EGFR Mutated NSCLC.
AstraZeneca 200
Large-scale testing (Phase 3)Active Not RecruitingNCT05184712
What this trial is testing

Phase 3 Clinical Study of AK112 for NSCLC Patients

Who this might be right for
Non-Squamous Non-small Cell Lung Cancer
Akeso 322
Testing effectiveness (Phase 2)UnknownNCT03647956
What this trial is testing

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation
The University of Hong Kong 40
Not applicableStudy completedNCT03750175
What this trial is testing

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

Who this might be right for
Colorectal Cancer MetastaticCirculating Tumor DNAKRAS Gene Mutation+3 more
Karen-Lise Garm Spindler 49
Early research (Phase 1)Study completedNCT01851096
What this trial is testing

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

Who this might be right for
Cancer
Esanex Inc. 17
Not applicableUnknownNCT03071705
What this trial is testing

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell AdenocarcinomaTyrosine Kinase MutationEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 120
Large-scale testing (Phase 3)Study completedNCT00496652
What this trial is testing

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Who this might be right for
Cancer of the Head and Neck
Danish Head and Neck Cancer Group 619
Early research (Phase 1)Study completedNCT00243854
What this trial is testing

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Indiana University 8
Not applicableUnknownNCT04007835
What this trial is testing

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 120
Early research (Phase 1)Ended earlyNCT02206763
What this trial is testing

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Sierra Oncology LLC - a GSK company 11
Not applicableUnknownNCT02851329
What this trial is testing

Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors

Who this might be right for
Non-small Cell Lung Cancer
Chinese Academy of Sciences 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789444
What this trial is testing

Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets

Who this might be right for
Non-Small Cell Lung CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Xiaorong Dong 53
Not applicableStudy completedNCT07838532
What this trial is testing

Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Activating Mutation
Xin Li 637
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07552558
What this trial is testing

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Who this might be right for
Head and Neck Squamous Cell CarcinomaHPV-Negative Squamous Cell Carcinoma
Washington University School of Medicine 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT04027647
What this trial is testing

Phase 2 Study of Dacomitinib in NSCLC

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV+2 more
National Cancer Centre, Singapore 118
Next Page